The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Authors :: Storti P
Toscani D
Airoldi I
Marchica V
Maiga S
Bolzoni M
Fiorini E
Campanini N
Martella E
Mancini C
Guasco D
Ferri V
Donofrio G
Aversa F
Amiot M
Giuliani N
Source :: Haematologica [Haematologica] 2016 Mar; Vol. 101 (3), pp. e107-10. Date of Electronic Publication: 2015 Dec 11.
Publication Year :: 2016

Subjects :: Animals
Caspase 3 genetics
Caspase 3 immunology
Cyclin-Dependent Kinase Inhibitor p27 genetics
Cyclin-Dependent Kinase Inhibitor p27 immunology
Disease Models, Animal
Humans
Hypoxia-Inducible Factor 1, alpha Subunit antagonists & inhibitors
Hypoxia-Inducible Factor 1, alpha Subunit immunology
Ikaros Transcription Factor genetics
Ikaros Transcription Factor immunology
Interferon Regulatory Factors genetics
Interferon Regulatory Factors immunology
Lenalidomide
Mice
Mice, Inbred NOD
Mice, SCID
Mitogen-Activated Protein Kinase 1 genetics
Mitogen-Activated Protein Kinase 1 immunology
Mitogen-Activated Protein Kinase 3 genetics
Mitogen-Activated Protein Kinase 3 immunology
Multiple Myeloma genetics
Multiple Myeloma immunology
Multiple Myeloma pathology
Plasma Cells immunology
Plasma Cells pathology
RNA, Small Interfering genetics
RNA, Small Interfering metabolism
S-Phase Kinase-Associated Proteins genetics
S-Phase Kinase-Associated Proteins immunology
Signal Transduction
Thalidomide pharmacology
Trans-Activators genetics
Trans-Activators immunology
Gene Expression Regulation, Neoplastic
Hypoxia-Inducible Factor 1, alpha Subunit genetics
Immunologic Factors pharmacology
Multiple Myeloma therapy
Plasma Cells drug effects
Thalidomide analogs & derivatives

Full Text Access

Tools